Cargando…

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET

SIMPLE SUMMARY: About 10–20% of breast cancer patients have a heterogeneous estrogen receptor expression. The diagnosis and treatment strategy remains controversial in these patients, especially regarding the metastatic pattern. The aim of our study was to investigate the occurrence and properties o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yizhao, Du, Xinyue, Zhao, Yannan, Gong, Chengcheng, Hu, Shihui, You, Shuhui, Song, Shaoli, Hu, Xichun, Yang, Zhongyi, Wang, Biyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323202/ https://www.ncbi.nlm.nih.gov/pubmed/35884590 http://dx.doi.org/10.3390/cancers14143531

Ejemplares similares

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
por: Liu, Cheng, et al.
Publicado: (2022)

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
por: Ma, Guang, et al.
Publicado: (2023)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2019)

Analyzing the Estrogen Receptor Status of Liver Metastases with [(18)F]-FES-PET in Patients with Breast Cancer
por: Boers, Jorianne, et al.
Publicado: (2021)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Evaluation of estrogen expression of breast cancer using (18)F-FES PET CT-A novel technique
por: Seenu, Vuthaluru, et al.
Publicado: (2020)

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging
por: Katzenellenbogen, John A.
Publicado: (2020)

Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016)

18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature
por: Bodapati, Sandhya, et al.
Publicado: (2022)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Application of a Novel (68)Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
por: Miao, Haitao, et al.
Publicado: (2022)

Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal (18)F-FES PET/CT
por: He, SiMin, et al.
Publicado: (2019)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
por: Zhao, Yannan, et al.
Publicado: (2021)

Image Quality and Interpretation of [(18)F]-FES-PET: Is There any Effect of Food Intake?
por: Boers, Jorianne, et al.
Publicado: (2020)

Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
por: Ivanidze, Jana, et al.
Publicado: (2021)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

2,4-Dichlorophenol Shows Estrogenic Endocrine Disruptor Activity by Altering Male Rat Sexual Behavior
por: Ferris Pasquini, Veronica, et al.
Publicado: (2023)

Home FES: An Exploratory Review
por: Taylor, Matthew J., et al.
Publicado: (2019)

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP
por: Wang, Ye, et al.
Publicado: (2023)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Distribution, expression of hexaploid wheat Fes1s and functional characterization of two TaFes1As in Arabidopsis
por: Lu, Yunze, et al.
Publicado: (2022)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

ZR-75-1 breast cancer models to study the utility of (18)F-FES by PET imaging
por: Ding, Ziteng, et al.
Publicado: (2021)

Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
por: Gu, Bingxin, et al.
Publicado: (2020)

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer
por: Wang, Jinyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q8lsbrl4toecmsc6k0amh6jl9p